| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a722744e77c81c5f5cf415087e2ee92b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-60 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-60 |
| filingDate |
1988-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1990-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14d20f679aab049e936069eacde2aeab |
| publicationDate |
1990-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-4933356-A |
| titleOfInvention |
Diflunisal potentiation of acetazolamide in the control of intraocular pressure |
| abstract |
The invention relates to an improved therapy to control intraocular pressure (IOP). More specifically, the present invention relates to an improved treatment of glaucoma patients to control ocular hypertension. It has now been found that an effective amount of diflunisal potentiates the action of certain heterocyclic sulfonamides such as acetazolamide to provide an improved hypotensive therapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02053160-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10363245-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006293390-A1 |
| priorityDate |
1988-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |